Episodes
![Skin Cancer Highlights at ASCO 2024](https://pbcdn1.podbean.com/imglogo/image-logo/9722812/vj-onc-pod-tile_300x300.png)
4 days ago
Skin Cancer Highlights at ASCO 2024
4 days ago
4 days ago
Welcome to another episode of VJ Oncology Podcasts! Today, we spotlight key advances in skin cancer research shared at ASCO 2024. Join us as six leading experts reveal groundbreaking findings from recent clinical trials.
First, Georgina Long from the University of Sydney discusses the NADINA trial, a landmark Phase III study on neoadjuvant immunotherapy for melanoma. Next, Omid Hamid from The Angeles Clinic presents early results from a Phase I trial of IMC-F106C in metastatic cutaneous melanoma. Hear insights from Meredith McKean, Sapna Patel, Joseph J. Sacco, and Rodabe Amaria on innovative therapies and trial results shaping the future of skin cancer treatment. Tune in for these and more exciting updates!
![iwCAR-T sessions: Clinical Advances in Head and Neck Cancer and Brain Tumors](https://pbcdn1.podbean.com/imglogo/image-logo/9722812/vj-onc-pod-tile_300x300.png)
Friday Jun 07, 2024
iwCAR-T sessions: Clinical Advances in Head and Neck Cancer and Brain Tumors
Friday Jun 07, 2024
Friday Jun 07, 2024
Welcome to another episode of VJ Oncology! In this episode, we delve into pioneering CAR-T strategies for head and neck cancers and brain tumors, as discussed at the recent iwCAR-T workshop in Miami, Florida.
Join Kedar Khartani from Moffitt Cancer Center and Susanna Baumeister from Dana-Farber Cancer Institute as they explore groundbreaking CAR-T approaches and clinical trials targeting glioblastoma and neuroblastoma. They address the challenges and future prospects of commercializing these therapies, particularly for rare and pediatric cancers.
Discover the exciting developments in ALK-targeting CAR-T cells for neuroblastoma and new antigen-selected TIL therapies for head and neck cancers. This episode offers valuable insights into the evolving landscape of cell therapy in oncology.
Don't miss this informative discussion! Subscribe and leave a review on your favorite podcast app. Follow us on Twitter @VJOncology and visit vjoncology.com for more content from the iwCAR-T workshop.
![ELCC 2024 highlights](https://pbcdn1.podbean.com/imglogo/image-logo/9722812/vj-onc-pod-tile_300x300.png)
Friday May 24, 2024
ELCC 2024 highlights
Friday May 24, 2024
Friday May 24, 2024
This week, we bring you key highlights from European Lung Cancer Congress (ELCC) 2024
which took place in Prague, Czech Republic, including the EVOKE-02, IMscin002,
FLAURA2, MARIPOSA-2 and PAPILLON clinical trials. Hear from Federico Cappuzzo, AUSL
della Romagna-Ravenna, Ravenna, Italy, Natalia Valdiviezo, Instituto Nacional de
Enfermedades Neoplásicas, Lima, Peru, Alexander Spira, Next Oncology-Virginia VCS,
Joshua Sabari, NYU Langone Health, New York, NY, as they talk on exciting results in lung
cancer.
![Key Updates from ESMO Breast 2024](https://pbcdn1.podbean.com/imglogo/image-logo/9722812/vj-onc-pod-tile_300x300.png)
Friday May 17, 2024
Key Updates from ESMO Breast 2024
Friday May 17, 2024
Friday May 17, 2024
In today's episode, we bring you key highlights from ESMO Breast 2024, diving into important discussions surrounding the latest research and clinical data regarding breast cancer. We bring insights from top field experts, set to enlighten you on new breakthroughs and developments, including updates from the DESTINY-Breast02 trial as well as first-line CDK4/6 inhibitor clinical data in HR+/HER2-advanced breast cancer.
![Bladder Cancer Awareness Month Part II: Management of UC in the UK](https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog9722812/VJO_Bladder_Thumbnail_1400_ew8z2c_300x300.jpg)
Friday May 10, 2024
Bladder Cancer Awareness Month Part II: Management of UC in the UK
Friday May 10, 2024
Friday May 10, 2024
In this podcast, we continue to commemorate Bladder Cancer Awareness Month in
May with a special limited series, where we invite a special guest to
discuss and share their expert perspectives within this ever evolving field.
This week, Rob Jones, MD, PhD, University of Glasgow, Glasgow, UK, will be talking about first-line treatment paradigms in bladder cancer, survivorship challenges, and the current state of bladder cancer treatment in the UK.
![Bladder Cancer Awareness Month Part I: The past, present, and future of ADCs](https://pbcdn1.podbean.com/imglogo/ep-logo/pbblog9722812/VJO_Bladder_Thumbnail_1400_rgxn3e_300x300.jpg)
Friday May 03, 2024
Bladder Cancer Awareness Month Part I: The past, present, and future of ADCs
Friday May 03, 2024
Friday May 03, 2024
In this podcast, we commemorate Bladder Cancer Awareness Month in
May with a special limited series, where we invite a special guest to
discuss and share their expert perspectives within this ever evolving field.
This week, Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer
Center, New York, NY, will be talking about antibody-drug conjugates,
which have made a big impact in the treatment landscape of bladder
cancer and other solid tumors. He will provide his thoughts on the
approval of enfortumab vedotin, managing toxicities, and the future of
ADCs
![BTOG 2024 Highlights](https://pbcdn1.podbean.com/imglogo/image-logo/9722812/vj-onc-pod-tile_300x300.png)
Friday Apr 26, 2024
BTOG 2024 Highlights
Friday Apr 26, 2024
Friday Apr 26, 2024
Join us for an enlightening podcast hosted by VJOncology, featuring a panel of renowned experts sharing the latest advancements in lung cancer research from BTOG 2024.
In the first segment, listeners are offered a deep dive into the early stages of lung cancer as Charles Swanton (Francis Crick Institute, London, UK) examines the correlation between air pollution exposure and cancer development. Following this, Thomas Newsom-Davies (Chelsea and Westminster Hospital NHS Foundation Trust, London, UK) provides insight into some of the exciting progress taking place in TNM staging, systematic staging, and immunotherapy. Mariana Brandao (Institute Jules Bordet, Brussels, Belgium) steers the discussion to the complex task of determining operability in non-small cell lung cancer. She emphasizes the importance of a comprehensive operability assessment, highlighting the challenges associated with the disease's complex heterogeneity, particularly in stage three patients.
Winding down the session, Robert Rintau (University of Cambridge & Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK,) weighs in on the implications of increased lung cancer survival rates and the evolving approach to treatment.
The podcast rounds off with reflections from Crispin Hiley (UCL, London, UK) on the HIT-Meso trial from and Sanjay Popat (The Royal Marsden NHS Foundation Trust, London, UK) reflects on the success of BTOG 2024 emphasizing the comprehensive representation of multidisciplinary teams dedicated to managing primary thoracic malignancies. Listen now to gain valuable insights into the rapidly evolving landscape of lung cancer treatment and research.
![Highlights from AACR 2024: KRYSTAL-1, FLAURA2, and EDGE](https://pbcdn1.podbean.com/imglogo/image-logo/9722812/vj-onc-pod-tile_300x300.png)
Friday Apr 12, 2024
Highlights from AACR 2024: KRYSTAL-1, FLAURA2, and EDGE
Friday Apr 12, 2024
Friday Apr 12, 2024
This week, we cover key updates from the American Association for Cancer Research (AACR) 2024 Annual Meeting, held in San Diego, CA. Hear from Scott Koptez, The University of Texas MD Anderson Cancer Center, Houston, TX, Rebecca Porter, Dana-Farber Cancer Institute, Boston, MA, Pasi Janne, Dana-Farber Cancer Institute, Boston, MA, and Elizabeth Swisher, Fred Hutchinson Cancer Center, Seattle, CA, as they discuss takeaways from the meeting.
![Updates in immunotherapy for head and neck cancer](https://pbcdn1.podbean.com/imglogo/image-logo/9722812/vj-onc-pod-tile_300x300.png)
Thursday Mar 28, 2024
Updates in immunotherapy for head and neck cancer
Thursday Mar 28, 2024
Thursday Mar 28, 2024
In this podcast, we highlight some of the latest updates in the use of immunotherapy to treat head and neck cancer. This week we will be joined by Nicolas Mach, MD, Hôpitaux Universitaires de Genève, Geneva, Switzerland; Emrullah Yilmaz, MD, PhD, Cleveland Clinic, Cleveland, OH; Emrullah Yilmaz, MD, PhD, Cleveland Clinic, Cleveland, OH; Ari Rosenberg, MD, University of Chicago, Chicago, IL and Nabil Saba, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA.
We will hear about the results of the SAKK 11/16 trial (NCT02999646) of the MVX-ONCO-1 vaccine, a Phase I dose expansion trial (NCT04429542) of BCA101, a bifunctional EGFR/TGFβ inhibitor, with pembrolizumab, and increasing T-cell responses in HPV-positive head and neck cancer with TheraT vectors, as well as other novel immunotherapy approaches.
For other head and neck cancer news, head over to our Head and Neck Cancer Channel.
Subscribe to our podcasts on Apple Podcasts, Podbean, and Spotify and join the conversation via X (formerly Twitter) @VJOncology. For more updates in the field, visit vjoncology.com.
![Updates in immunotherapy for skin cancer](https://pbcdn1.podbean.com/imglogo/image-logo/9722812/vj-onc-pod-tile_300x300.png)
Friday Mar 22, 2024
Updates in immunotherapy for skin cancer
Friday Mar 22, 2024
Friday Mar 22, 2024
In this podcast, we highlight some of the latest updates in the use of immunotherapy to treat skin cancer. This week, we will be joined by Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA; Paolo Ascierto, MD, Istituto Tumori Fondazione Pascale, Naples, Italy; Georgina Long, PhD, MBBS, FRACP, FAHMS, The University of Sydney, North Sydney, Australia; and Karijn Suijkerbuijk, MD, PhD, UMC Utrecht, Utrecht, The Netherlands.
We will hear on the impact of T-Cell therapies, such as lifileucel, in patients with melanoma; results of the 7-year CheckMate 238 trial (NCT02388906) of nivolumab; effective sequencing of treatments in the SECOMBIT trial (NCT02631447); and challenges in managing immunotherapy related adverse events.
If you would like to learn more about the recent approval of lifileucel by the FDA, you can find our feature article here. For other skin cancer news, be sure to visit our dedicated Skin Cancer Channel.
Subscribe to our podcasts on Apple Podcasts, Podbean, and Spotify and join the conversation via X (formerly Twitter) @VJOncology. For more updates in the field, visit vjoncology.com.